Promising News from Sarepta on Exon 51 Skipping Trial - PPMD Community

Promising News from Sarepta on Exon 51 Skipping Trial - PPMD Community: The much-anticipated 48-week results on eteplirsen, a drug designed to skip exon 51, were presented today by Sarepta Therapeutics�on a webinar and press release. On the webinar, Sarepta’s Chief Executive Chris Garabedian presented data about the dystrophin found in study participants’ muscle biopsies and the 6-minute walk results.